

	2002	2002					2002	2003
	Pfizer	Pharmacia	Transaction	Adjustments			Pfizer	Pfizer
	Actual	Actual	Eliminations	Additions	Financing	Goodwill	Proforma	Forecast
Cash and Equivalents	12,950	2,710					15,660	12,343
Accounts Receivable	5,785	2,457	(366)				7,876	8,775
Inventory	2,678	2,177		1,630			6,485	5,837
Deferred Taxes	1,907						1,907	1,185
Other Current Assets	1,461	1,936					3,397	1,601
Total Current Assets	24,781	9,280	(366)	1,630	0	0	35,325	29,741
Net Property, Plant & Equipment	10,712	5,683		811			17,206	18,287
Finite Life Intangibles	324	393		25,371			26,088	5,955
Indefinite Life Intangibles	597			10,349			10,946	30,395
Goodwill	1,200	1,150	(1,150)			22,556	23,756	22,306
Investment in Uncons. Subs.	0						0	0
Deferred Taxes	0						0	532
Other Long-Term Assets	8,742	2,011		40			10,793	9,559
Total Assets	46,356	18,517	(1,516)	38,201	0	22,556	124,114	116,775
Accounts Payable	1,620	780	(366)				2,034	2,601
Deferred Taxes	0						0	0
Short Term Debt	8,669	854					9,523	8,818
Other Current Liabilities	8,266	3,524		2,277			14,067	12,238
Total Current Liabilities	18,555	5,158	(366)	2,277	0	0	25,624	23,657
Revolver/New Debt Financing	3,140	2,585		370			6,095	5,755
New Acquisition Debt							0	
Non-Redeemed Existing Straight Debt							0	
Non-Redeemed Existing Convertible Debt							0	
Total Debt	3,140	2,585	0	370	0	0	6,095	5,755
Deferred Taxes	364	121		12,896			13,381	13,238
Minority Interest	0						0	0
Other Long-Term Liabilities	4,347	2,670		1,557			8,574	8,748
Total Liabilities	26,406	10,534	(366)	17,100	0	0	53,674	51,398
Straight Preferred Stock							0	
Convertible Preferred Stock							0	
Common Stockholders' Equity	19,950	7,983	(7,983)	(5,277)	55,767		70,440	65,377
Total Liabilities & Shareholders' Equity	46,356	18,517	(8,349)	11,823	55,767	0	124,114	116,775
			6,833	28,378	55,767	22,556		
Debt	11,809.0	3,439.0					15,618.0	14,573.0
Total Cap	31,759.0	11,422.0					86,058.0	79,950.0
Debt/Cap	37%	30%					18%	18%

Barry M Frohlinger, Inc.

	2002 Pfizer Actual	2002 Pharmacia Actual	Transaction Adjustments			2002 Pfizer Proforma	2003		2003 Pfizer proforma
			Eliminations	Additions	Financing		Pfizer actual	Pfizer proforma	
Revenues	32,373	13,993	(1,368)			44,998	45,188	3,682	48,870
Cost of Goods Sold (excl. Deprec.)	3,037	2,622	17			5,676	7,937	770	8,707
Gross Profit (Before Deprec.)	29,336	11,371	(1,385)	0	0	39,322	37,251	2,913	40,164
Selling, General & Administration	10,846	6,179	(1,345)			15,680	15,242	1,410	16,652
R&D	5,176	2,359				7,535	7,131	688	7,819
Merger Costs	630	68				698	1,058	20	1,078
IPR&D	0	0				0		0	0
EBITDA (Operating Cash Flow)	12,684	2,765	(40)	0	0	15,409	13,820	795	14,615
Depreciation	1,008	455		275		1,738	1,895	133	2,108
Amortization of Intangibles	28	69		2,830		2,927	2,183	20	3,029
Amortization of Goodwill						0			0
EBIT (Operating Income)	11,648	2,241	(40)	(3,105)	0	10,744	9,742	642	(906)
Other Expenses (Income):									
Equity Earnings in Uncons. Subs.						0		0	0
Non-Operating Expense (Income)	(72)	(1,065)				(1,137)	1,558	(311)	1,247
Interest (Income)	(76)	0		(40)		(116)	(131)	0	(143)
New Revolver Interest Expense						0		0	0
New Acquisition Debt						0		0	0
Existing Debt Interest Expense						0		0	0
Pre-Tax Income	11,796	3,306	(40)	(3,065)	0	11,997	8,315	953	(894)
Income Taxes	2,609	869	(14)	(1,073)	0	2,391	1,621	249	(313)
Net Income	9,187	2,437	(26)	(1,992)	0	9,606	6,694	703	(581)
Minority Interest in Net Income	6	0				6	3		3
Adjusted Net Income	9,181	2,437	(26)	(1,992)	0	9,600	6,691	703	(581)
Preferred Dividends									
Net Income to Common	9,181	2,437	(26)	(1,992)	0	9,600	6,691	703	(581)
Extraordinary Charges (Income)	55	0				55	(2,271)		
Adjusted Net Income to Common	9,126	2,437	(26)	(1,992)	0	9,545	8,962	703	(581)
Basic Earnings Per Share	1.49	1.88				1.21	0.93		0.94
Basic Shares Outstanding (MM)	6,156	1,293			517	7,966	7,213		7,213
Diluted Earnings Per Share	1.46	1.85				1.18	1.23		0.94
Diluted Shares Outstanding (MM)	6,241	1,315			526	8,082	7,286		7,286